Antiviral Drug News and Research

RSS

China, WHO to collaborate on flu research center

Chinese and WHO officials last week agreed to open a flu research center in Beijing, Bloomberg reports. "The new collaborating center for reference and research on influenza will join a network of WHO-affiliated labs in Atlanta, London, Tokyo and Melbourne that monitor flu strains and make recommendations on vaccines to fight the virus," the news service writes

17 Nov 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Inovio Biomedical Corporation today reported financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

UK research funders announce support for a series of H1N1 2009 research projects

Leading UK research funders today announce -7.5 million of funding for a series of projects aimed at understanding the development and spread of pandemic influenza H1N1 2009 - or 'swine flu'. The research will look at every aspect of the virus, on pig farms, in pig and human populations, and in hospital intensive care units.

11 Nov 2009

UCSF HIV researchers receive two NIH grants to improve health of HIV positive patients

UCSF HIV researchers have received two NIH grants of $1 million each to study the use of web-based, patient controlled personal health records to improve health and HIV prevention outcomes for HIV positive patients.

6 Nov 2009

HHS announces contract awards for up to 120,000 treatment courses of intravenous antiviral drugs

The U.S. Department of Health and Human Services (HHS) today announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients.

6 Nov 2009

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

Swine flu treatments, safety issues prompt health workers to speak out

In anticipation of new swine flu cases, medical workers are looking for new ways help their patients - and protect themselves.

21 Oct 2009

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Early action, especially rapid rollout of vaccines, is extremely effective in reducing the attack rate of the H1N1 influenza virus, according to a simulation model of a pandemic outbreak reported in a new study in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

14 Oct 2009

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

Wal-Mart Stores, Inc. announced today that more than 4,000 Walmart and Sam's Club pharmacies nationwide will address the national shortage of Tamiflu® oral suspension by converting the capsule to liquid form.

12 Oct 2009

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

In response to new economic and regulatory realities, CytoDyn, Inc. has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS.

9 Oct 2009

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

18 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains.

14 Sep 2009

Plant extract could lead to new drug development for H1N1

Scientists in China have discovered that roots of a plant used a century ago during the great Spanish influenza pandemic contains substances with powerful effects in laboratory experiments in killing the H1N1 swine flu virus that now threatens the world.

10 Sep 2009

Cepheid's Flu Panel test to provide 45-minute identification of Flu A infection

Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types.

9 Sep 2009

Seeplex FluA ACE subtyping test enables simultaneous detection of four major influenza A subtypes

Seegene today released a new influenza A sub-type screening test, Seeplex FluA ACE Subtyping, that enables simultaneous detection of pandemic novel influenza A (H1N1), seasonal human influenza A H1, seasonal human influenza A H3 and avian influenza A H5 in a single reaction.

1 Sep 2009

NIAID funds Nanotherapeutic for developing an inhaled version of the injectable antiviral drug

Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).

25 Aug 2009

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

22 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

George Rehm and David Mahoney joins Adamas' Board of Directors

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, the company announced the election of George M. Rehm, Managing Partner of aeris CAPITAL AG, and David L. Mahoney, a private equity investor, to the company's Board of Directors.

19 Aug 2009